SCHEMBL7305728

SCHEMBL7305728

CCCCCCCC(O)C(=O)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CETP P11597 3/20 0.52
ALDH1A1 P00352 3/20 0.51
CYP3A4 P08684 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GPR84 Q9NQS5 3/20 0.50
FFAR1 O14842 1/20 0.50
CSNK1E P49674 1/20 0.49
SIRT2 Q8IXJ6 2/20 0.48
SIRT1 Q96EB6 2/20 0.48
MEN1 O00255 1/20 0.48
HPGD P15428 1/20 0.48
KMT2A Q03164 1/20 0.48
CNR2 P34972 1/20 0.48
SIRT3 Q9NTG7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7305733 1.00 CETP (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL27424922 1.00 CETP (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL21245794 1.00 CETP (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL2677628 1.00 CETP (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL3736932 1.00 CETP (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL16648466 1.00 CETP (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL16648564 0.98 ALDH1A1 (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL16648567 0.98 ALDH1A1 (0.52) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL30759387 0.94 ALDH1A1 (0.54) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL6869938 0.94 ALDH1A1 (0.54) CETPALDH1A1CYP3A4TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3441399-A1 NOVEL CYCLIC DEPSIPEPTIDE DERIVATIVES AND HARMFUL ORGANISM CONTROL AGENTS COMPRISING THE SAME Meiji Seika Pharma Co., Ltd. (JP) 2019-02-13 EP disclosed
EP-2862872-B1 NOVEL CYCLIC DEPSIPEPTIDE DERIVATIVE AND PEST CONTROL AGENT COMPRISING SAME MEIJI SEIKA PHARMA CO LTD (JP) 2018-09-19 EP disclosed
CN-104540845-B Novel cyclic depsipeptide derivative and pest control agent containing same 明治制果药业株式会社 2018-01-26 CN disclosed
US-20170215422-A1 NOVEL CYCLIC DEPSIPEPTIDE DERIVATIVES AND HARMFUL ORGANISM CONTROL AGENTS COMPRISING THE SAME MEIJI SEIKA PHARMA CO LTD (JP) 2017-08-03 US disclosed
US-20150166608-A1 NOVEL CYCLIC DEPSIPEPTIDE DERIVATIVES AND HARMFUL ORGANISM CONTROL AGENTS COMPRISING THE SAME THE KITASATO INSTITUTE (JP) 2015-06-18 US disclosed
EP-2862872-A1 NOVEL CYCLIC DEPSIPEPTIDE DERIVATIVE AND PEST CONTROL AGENT COMPRISING SAME Meiji Seika Pharma Co., Ltd. (JP) 2015-04-22 EP disclosed
CN-104540845-A Novel cyclic depsipeptide derivative and pest control agent containing same MEIJI SEIKA PHARMA CO LTD 2015-04-22 CN disclosed
EP-0575844-B1 Hydroxamic acid derivatives and pharmaceutical compositions thereof HOFFMANN LA ROCHE (CH) 1998-01-21 EP disclosed
EP-0575844-A2 Hydroxamic acid derivatives and pharmaceutical compositions thereof F. HOFFMANN-LA ROCHE AG (CH) 1993-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170215422-A1 NOVEL CYCLIC DEPSIPEPTIDE DERIVATIVES AND HARMFUL ORGANISM CONTROL AGENTS COMPRISING THE SAME VIP, DDT, NPPA CETP 1866/4885ALDH1A1 3144/4885CYP3A4 2819/4885
US-20150166608-A1 NOVEL CYCLIC DEPSIPEPTIDE DERIVATIVES AND HARMFUL ORGANISM CONTROL AGENTS COMPRISING THE SAME VIP, DDT, NPPA CETP 1866/4885ALDH1A1 3144/4885CYP3A4 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.